AERI:NSD-Aerie Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 14.03

Change

0.00 (0.00)%

Market Cap

USD 0.65B

Volume

1.36M

Average Target Price

USD 30.36 (+116.37%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-31 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.82B 143.75 7.70
MNTA Momenta Pharmaceuticals, Inc

N/A

USD3.70B N/A N/A
CRON Cronos Group Inc

N/A

USD2.29B 2.64 N/A
PCRX Pacira BioSciences, Inc

N/A

USD1.85B 870.20 44.19
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.55B 19.72 15.40
TCDA Tricida, Inc

N/A

USD1.34B N/A N/A
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.27B 11.49 7.08
TLRY Tilray, Inc

N/A

USD1.23B N/A N/A
PAHC Phibro Animal Health Corporati..

N/A

USD1.06B 29.89 14.75
ATNX Athenex, Inc

N/A

USD0.89B N/A N/A

ETFs Containing AERI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.95% 24% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.95% 24% F 14% F
Trailing 12 Months  
Capital Gain -61.48% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.48% 21% F 9% F
Trailing 5 Years  
Capital Gain 15.95% 78% C+ 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.95% 78% C+ 57% F
Average Annual (5 Year Horizon)  
Capital Gain 29.77% 96% A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.77% 96% A 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 87.73% 7% F 9% F
Risk Adjusted Return 33.94% 87% B+ 55% F
Market Capitalization 0.65B 74% C 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.26 40% F 23% F
Price / Cash Flow Ratio -4.33 66% D 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -125.73% 35% F 11% F
Return on Invested Capital -64.24% 25% F 15% F
Return on Assets -33.92% 24% F 13% F
Debt to Equity Ratio 113.00% 21% F 21% F
Technical Ratios  
Short Ratio 10.98 18% F 8% F
Short Percent 29.13% 5% F 8% F
Beta 0.95 73% C 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector